These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1001353)

  • 1. Comparison of the pharmacokinetics of intravenous dl-propranolol in borderline and permanent hypertension.
    Weiss YA; Safar ME; Chevillard C; Frydman A; Simon A; Lemaire P; Alexandre JM
    Eur J Clin Pharmacol; 1976; 10(6):387-93. PubMed ID: 1001353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of the absorption and removal of propranolol in hypertensive patients during therapy.
    Chidsey CA; Morselli P; Bianchetti G; Morganti A; Leonetti G; Zanchetti A
    Circulation; 1975 Aug; 52(2):313-8. PubMed ID: 1149212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No stereoselective first-pass hepatic extraction of propranolol.
    Jackman GP; McLean AJ; Jennings GL; Bobik A
    Clin Pharmacol Ther; 1981 Sep; 30(3):291-6. PubMed ID: 7273593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits].
    Vinçon G; Ploux D; Pehourcq F; Albin H
    J Pharmacol; 1983; 14(1):47-55. PubMed ID: 6834851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of oral activated charcoal on propranolol pharmacokinetics following intravenous administration to rabbits.
    al-Meshal MA; el-Sayed YM; al-Angary AA; al-Dardiri MM
    J Clin Pharm Ther; 1993 Feb; 18(1):39-44. PubMed ID: 8473358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous propranolol administration: a method for rapidly achieving and sustaining desired plasma levels.
    McAllister RG
    Clin Pharmacol Ther; 1976 Nov; 20(5):517-23. PubMed ID: 975723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics and cardiac effects of propranolol in humans.
    Ochs HR; Grube E; Greenblatt DJ; Knüchel M; Bodem G
    Klin Wochenschr; 1982 May; 60(10):521-5. PubMed ID: 7098380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoproterenol sensitivity and total body clearance of propranolol in hypertensive patients.
    London GM; Safar ME; Weiss YA; Milliez PL
    J Clin Pharmacol; 1976 Apr; 16(4):174-83. PubMed ID: 1262530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive effect of propranolol in conscious spontaneously hypertensive rats: central hemodynamics, plasma volume, and renal function during beta-blockade with propranolol.
    Smits JF; Coleman TG; Smith TL; Kasbergen CM; van Essen H; Struyker-Boudier HA
    J Cardiovasc Pharmacol; 1982; 4(6):903-14. PubMed ID: 6185781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of propranolol pharmacokinetics to antihypertensive effect and beta-adrenergic blockade in the treatment of hypertension.
    Krediet RT; Dunning AJ; Offerhaus L
    Eur J Clin Pharmacol; 1980 Nov; 18(5):391-4. PubMed ID: 6108222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leakage of dl-propranolol from cerebrospinal fluid to the bloodstream in the rabbit.
    Anderson WP; Korner PI; Bobik A; Chalmers JP
    J Pharmacol Exp Ther; 1977 Aug; 202(2):320-5. PubMed ID: 886469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of propranolol during pregnancy.
    O'Hare MF; Kinney CD; Murnaghan GA; McDevitt DG
    Eur J Clin Pharmacol; 1984; 27(5):583-7. PubMed ID: 6519163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic haemodynamics in borderline arterial hypertension: responses to static exercise before and under the influence of propranolol.
    Sannerstedt R; Julius S
    Cardiovasc Res; 1972 Jul; 6(4):398-403. PubMed ID: 5045600
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol.
    Regårdh CG; Johnsson G; Jordö L; Lungborg P; Persson BA; Rönn O
    J Cardiovasc Pharmacol; 1980; 2(6):715-23. PubMed ID: 6160322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological determinants of propranolol disposition in man.
    Kornhauser DM; Wood AJ; Vestal RE; Wilkinson GR; Branch RA; Shand DG
    Clin Pharmacol Ther; 1978 Feb; 23(2):165-74. PubMed ID: 620476
    [No Abstract]   [Full Text] [Related]  

  • 16. Beta-adrenergic blockade in essential hypertension. Effects of propranolol on hemodynamic parameters and plasma renin activity.
    Hansson L
    Acta Med Scand Suppl; 1973; 550():1-40. PubMed ID: 4201751
    [No Abstract]   [Full Text] [Related]  

  • 17. Indocyanine green kinetics characterize blood volume and flow distribution and their alteration by propranolol.
    Niemann CU; Henthorn TK; Krejcie TC; Shanks CA; Enders-Klein C; Avram MJ
    Clin Pharmacol Ther; 2000 Apr; 67(4):342-50. PubMed ID: 10801242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers.
    Cheymol G; Poirier JM; Barre J; Pradalier A; Dry J
    J Clin Pharmacol; 1987 Nov; 27(11):874-9. PubMed ID: 3429695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased clearance of propranolol in thyrotoxicosis.
    Feely J; Stevenson IH; Crooks J
    Ann Intern Med; 1981 Apr; 94(4 pt 1):472-4. PubMed ID: 7212504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rest and exercise hemodynamic effects of sequential alpha-1-adrenoceptor (trimazosin) and beta-adrenoceptor (propranolol) antagonism in essential hypertension.
    Nelson GI; Silke B; Hussain M; Verma SP; Taylor SH
    Am Heart J; 1984 Jul; 108(1):124-31. PubMed ID: 6731261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.